HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
Line 124: Line 124:
|
|
|
|
|}[[File:t(16;16)(p13.1;q22).png|t(16;16)(p13.1;q22)|frame|center]] [[File:inv(16)(p13.1q22).png|inv(16)(p13.1q22)|frame|center]] [[File:Inv(16)(p13.1q22) karyogram and insert (8-7-18).png|inv(16)(p13.1q22). Courtesy of Karen Kundinger, Comprehensive Genetic Services, Milwaukee, WI|frame|center]]
|}[[File:t(16;16)(p13.1;q22).png|t(16;16)(p13.1;q22)|frame|alt=|left]] [[File:inv(16)(p13.1q22).png|inv(16)(p13.1q22)|frame|alt=|left]] [[File:Inv(16)(p13.1q22) karyogram and insert (8-7-18).png|inv(16)(p13.1q22). Courtesy of Karen Kundinger, Comprehensive Genetic Services, Milwaukee, WI|frame|center]]<br />
 
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 480: Line 479:
The <u>epidemiology/prevalence</u> of this disease is detailed below:
The <u>epidemiology/prevalence</u> of this disease is detailed below:


* Approximately 5-8% of AML cases have inv(16)(p13.1q22) or t(16;16)(p13.1;q22). More common in males and younger adults.
*Approximately 5-8% of AML cases have inv(16)(p13.1q22) or t(16;16)(p13.1;q22). More common in males and younger adults.


The <u>clinical features</u> of this disease are detailed below:
The <u>clinical features</u> of this disease are detailed below:
Line 490: Line 489:
The <u>sites of involvement</u> of this disease are detailed below:
The <u>sites of involvement</u> of this disease are detailed below:


* Bone marrow
*Bone marrow


The <u>morphologic features</u> of this disease are detailed below:  
The <u>morphologic features</u> of this disease are detailed below:  
Line 515: Line 514:
*populations with granulocytic differentiation positive for CD13, CD33, CD15, CD65 and MPO
*populations with granulocytic differentiation positive for CD13, CD33, CD15, CD65 and MPO
*populations with monocytic differentiation, positive for CD14, CD4, CD11c, CD11b, CD11c, CD64, CD36 and lysozyme
*populations with monocytic differentiation, positive for CD14, CD4, CD11c, CD11b, CD11c, CD64, CD36 and lysozyme
Positive (universal) -
Positive (majority) -
Positive (subset) -
Negative (universal) -
Negative (subset) -


==Links==
==Links==